Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 2

Clinical Characteristics of 195 Cases of COVID-19 with Gastrointestinal Symptoms

Sayfa
148–154
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Patients with GI symptoms were more likely to have increased PCT and decreased lymphocyte count.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), have fever, dry cough, dyspnea, and fatigue.
📊
Temel Bulgular & Veri:The purpose of this study was to explore the relationship between COVID-19 and gastrointestinal (GI) symptoms.
💡
Sonuç & Katkı:Patients with GI symptoms were more likely to have increased PCT and decreased lymphocyte count.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), have fever, dry cough, dyspnea, and fatigue. The disease has now become a global pandemic. The purpose of this study was to explore the relationship between COVID-19 and gastrointestinal (GI) symptoms. Methods: We collected and analyzed data on patients with laboratory-confirmed COVID-19 by high-throughput sequencing or reverse transcription-polymerase chain reaction. We reviewed electronic medical records of 405 hospitalized COVID-19 patients in the Third Hospital of Wuhan. Results: Among the 405 confirmed patients, 210 had no GI symptoms, 195 had GI symptoms, and the first symptom of 155 patients was GI. The prevalence of vascular and digestive diseases in the group with GI symptoms was significantly higher than in the group without GI symptoms. In patients with GI symptoms, the proportion with fever, cough, dysphoria, chest tightness, poor appetite, chest pain, and pharyngeal pain was significantly higher than in those without GI symptoms. There was no significant difference in imaging between the 2 groups. In patients with GI symptoms, the proportion with increased procalcitonin (PCT) level and decreased lymphocyte count was significantly higher than in those without GI symptoms. Conclusion: COVID-19 patients with GI symptoms had significantly more vascular and digestive system diseases and were more likely to have clinical manifestations of fever, cough, poor appetite, chest tightness, chest pain, insomnia, and pharyngeal pain. There were more patients with diarrhea, nausea, and vomiting. Patients with GI symptoms were more likely to have increased PCT and decreased lymphocyte count.

🔖

Bu Makaleye Atıf Yap

ZHAN, T., TANG, Y., HAN, Z., ZHU, Q., TAN, J., LIU, M., CAI, Y., HUANG, M., CHEN, X., CHENG, X., DENG, J., HUANG, X., TIAN, X. (2021). Clinical Characteristics of 195 Cases of COVID-19 with Gastrointestinal Symptoms. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 2, 148–154. https://ajindex.com/articles/408862

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Ramphul K, Mejias SG. Coronavirus disease: a review of a new threat to public health. Cureus. 2020 Mar 15
  2. 12(3):e7276. [CrossRef] 2. Henry BM, Vikse J. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020 May 7
  3. 382(19):1860–1861. [CrossRef] 3. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020 May
  4. 158(6):1518–1519. [CrossRef] 4. Kotfis K, Skonieczna-Żydecka K. COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol Intensive Ther. 2020
  5. 52(2):171–172. [CrossRef] 5. Silva AAMD. On the possibility of interrupting the coronavirus (COVID-19) epidemic based on the best available scientific evidence. Rev Bras Epidemiol. 2020 Mar 16
  6. e200021. [CrossRef] 6. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020 Jun
  7. 83(6):521–523. [CrossRef] 7. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Arab J Gastroenterol. 2020 Mar
  8. 21(1):3–8. [CrossRef] 8. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Feb
  9. 264–266. [CrossRef] 9. Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20
  10. 28(2):100–106. [CrossRef] 10. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul
  11. 75(7):1730–1741. [CrossRef] 11. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15
  12. 395(10223):507–513. [CrossRef] 12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15
  13. 395(10223):497–506. [CrossRef] 13. Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China (reply). N Engl J Med. 2020 Feb 15
  14. 395(10223):497–506.[CrossRef] 14. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. Gastroenterology. 2020 Jul
  15. 159(1):373–375.e2. [CrossRef] 15. Henry BM, de Oliveira MHS, Benoit J, Lippi G. Gastrointestinal symptoms